TrivarX Limited Stock

Equities

TRI

AU0000300196

Pharmaceuticals

End-of-day quote Australian S.E. 18:00:00 2024-04-28 EDT 5-day change 1st Jan Change
0.026 AUD 0.00% Intraday chart for TrivarX Limited +8.33% -13.33%

Financials

Sales 2022 1.01M 661K 902K Sales 2023 960K 631K 862K Capitalization 4.55M 2.99M 4.08M
Net income 2022 -12M -7.89M -10.76M Net income 2023 -3M -1.97M -2.69M EV / Sales 2022 3.15 x
Net cash position 2022 966K 635K 867K Net cash position 2023 104K 68.21K 93.11K EV / Sales 2023 4.63 x
P/E ratio 2022
-0.24 x
P/E ratio 2023
-1.11 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 71.74%
More Fundamentals * Assessed data
Dynamic Chart
1 week+8.33%
Current month-10.34%
1 month-10.34%
3 months-3.70%
6 months+18.18%
Current year-13.33%
More quotes
1 week
0.02
Extreme 0.023
0.03
1 month
0.02
Extreme 0.023
0.03
Current year
0.02
Extreme 0.02
0.04
1 year
0.02
Extreme 0.02
0.04
3 years
0.02
Extreme 0.02
0.26
5 years
0.02
Extreme 0.02
0.64
10 years
0.02
Extreme 0.02
10.50
More quotes
Managers TitleAgeSince
Chief Tech/Sci/R&D Officer - -
Chief Operating Officer - 22-12-31
Director/Board Member - 22-09-18
Members of the board TitleAgeSince
Director/Board Member - 23-02-14
Director/Board Member - 22-09-18
Chairman - 22-08-24
More insiders
Date Price Change Volume
24-04-28 0.026 0.00% 1 053 956
24-04-26 0.026 0.00% 2,035,518
24-04-24 0.026 +4.00% 66,587
24-04-23 0.025 +4.17% 414,847
24-04-22 0.024 0.00% 550,000

End-of-day quote Australian S.E., April 28, 2024

More quotes
TrivarX Limited, formerly Medibio Limited, is an Australia-based mental health technology company engaged in the use of objective measures to aid in the early detection and screening of mental health conditions. Through the Company’s corporate health product, it offers mental well-being solutions for businesses and is also developing products to serve the healthcare provider market. The principal activity of the Company is conducting clinical research, product development and early-stage commercialization of a mental health technology using objective biomarkers to assist in the screening, diagnosing, monitoring, and management of depression and other mental health conditions. It has launched its consumer mobile application to help measure, monitor, and manage stress, called LUCA. LUCA is a biometric assessment tool that measures sleep stress, activity stress, and cardiac stress that allows consumers to monitor their daily stress levels through their own personal wearable device.
More about the company

Chiffre d''affaires - Rate of surprise